Digital Proteomics is now Abterra Biosciences
Truly human antibody therapeutics.
Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.
Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!
REPTOR™
Next-Gen Sequencing Hybridoma
REPTOR™
Next-Gen Sequencing Bulk B Cells
REPTOR™
Next-Gen Sequencing Hit Expansion
REPTOR™
Next-Gen Sequencing Display Library
ALICANTO®
Rabbit Monoclonal Antibody Discovery
ALICANTO®
Single Domain (VHH) Antibody Discovery
ALICANTO®
Human Antibody Discovery
VALENS™
Protein Sequence Confirmation
VALENS™
Antibody Protein Sequencing
Our partners’ success means everything to us
I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.
Latest News
PEGS Boston Summit 2021 Presentation
Abstract: Next-generation sequencing of antibody repertoires has provided new insights into natural immune responses. The correlation between the B-cell receptor repertoire and the serological antibody repertoire has only been analyzed in a small number of studies. ...
Abterra Bio Seattle Angel Conference Winner
We’re excited to announce that Abterra Bio has been chosen as the Winner of the 19th Seattle Angel Conference and the Audience Favorite Award. This year, there were 81 start-up companies from all over the US that had applied. The selection process took around 2-3...
Digital Proteomics is Abterra Biosciences
We're excited to announce that Digital Proteomics is now Abterra Biosciences. Our vision for the business has evolved and it's time to realign our name with our capabilities; we have developed core technologies that are driving our partners' antibody discovery...
We are a CONNECT Cool Company 2021!
We’re excited to announce that Abterra Biosciences has been selected as "A Cool Company" for the second year in a row by CONNECT. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences...
Scientific Updates
De Novo Antibody Sequencing Case Study
Abterra Bio uses bioinformatics and mass spectrometry to reconstructs the full amino acid sequence of both antibody chains. We’ve successfully sequenced human, mouse, rat, hamster, rabbit, and llama antibodies. This approach can be applied across any species and...
New Publication Reveals Ebolavirus-Neutralizing Monoclonal Antibodies
Abterra Biosciences, together with VUMC Vaccine Center, Mapp Bio, PNNL, UTMB Health, Ragon Institute, Integral Molecular, and La Jolla Institute, recently published a paper describing the discovery of Ebolavirus-neutralizing antibodies from convalescent plasma.Read...
Immune Repertoire Sequencing in Human
Immune repertoire sequencing enables deeper understanding of the adaptive immune response [1]. Abterra Biosciences has developed Reptor™, a flexible immune repertoire sequencing and analysis service. In this study, we analyzed the B-cell receptor (BCR) repertoire...
Clonal Hit-Expansion Case Study
Abterra Bio uses next-generation sequencing to mine the clonal lineage of serum-identified antibodies. This method rescues relatives of hits that are within a clone and increases diversity in your antibody discovery campaign. Contact us to learn more about how our...
Every day, we strive to help our partners and collaborators push the boundaries of their science.
